研報掘金丨長江證券:首予艾力斯“買入”評級,持續拓寬護城河
長江證券研報指出,艾力斯伏美替尼方興未艾,持續拓寬護城河。公司是一家聚焦腫瘤治療的創新藥企,依託核心產品伏美替尼的快速放量,已成功進入盈利週期。伏美替尼一線/二線治療EGFR突變陽性NSCLC療效與安全性雙優,具備BIC潛力。目前,公司正與美國ArriVent合作,聯合推進EGFR ex20ins 和EGFR PACC 突變NSCLC的全球臨牀研究,獲批上市後有望以三倍用藥劑量持續貢獻增量,打開成長天花板。公司通過外部引進持續豐富管線,先後從基石藥業引入RET 抑制劑普拉替尼,以及從加科思引進KRAS G12C抑制劑戈來雷賽與SHP2 抑制劑JAB-3312,進一步完善腫瘤產品佈局。首次覆蓋,給予“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.